Katy Knight

472 total citations
8 papers, 253 citations indexed

About

Katy Knight is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Katy Knight has authored 8 papers receiving a total of 253 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Genetics and 4 papers in Rheumatology. Recurrent topics in Katy Knight's work include Chronic Myeloid Leukemia Treatments (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). Katy Knight is often cited by papers focused on Chronic Myeloid Leukemia Treatments (7 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (4 papers). Katy Knight collaborates with scholars based in United Kingdom, Canada and United States. Katy Knight's co-authors include Richard E. Clark, José M. Rojas, L Wang, Lihui Wang, Claire Lucas, Andrea Davies, Munir Pirmohamed, Steven Lane, Zahra Raisi‐Estabragh and Sobhan Vinjamuri and has published in prestigious journals such as Journal of Clinical Oncology, Leukemia and Experimental Hematology.

In The Last Decade

Katy Knight

8 papers receiving 244 citations

Peers

Katy Knight

HEMAT

GENET

RHEUM

ONCOL

IMMUN

Hyacinthe Johnson‐Ansah France

Fabian Lang Germany

Nataliia Glushko Ukraine

Cristina Bucelli Italy

Danko Martincic United States

Uwe Schwindel Germany

Lauren T. Adrian United States

María Soledad Undurraga Chile

Mindaugas Jurgutis United Kingdom

R. Hehlmann Germany

Hyacinthe Johnson‐Ansah France

Katy Knight

353 ×2.0

HEMAT

293 ×2.4

GENET

161 ×1.9

RHEUM

90 ×1.2

ONCOL

26 ×0.4

IMMUN

Citations per year, relative to Katy Knight Katy Knight (= 1×) peers Hyacinthe Johnson‐Ansah

Countries citing papers authored by Katy Knight

Since Specialization

Citations

This map shows the geographic impact of Katy Knight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katy Knight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katy Knight more than expected).

Fields of papers citing papers by Katy Knight

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katy Knight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katy Knight. The network helps show where Katy Knight may publish in the future.

Co-authorship network of co-authors of Katy Knight

This figure shows the co-authorship network connecting the top 25 collaborators of Katy Knight. A scholar is included among the top collaborators of Katy Knight based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katy Knight. Katy Knight is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Francis, Sebastian, Claire Lucas, Steven Lane, et al.. (2013). A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. Leukemia Research. 37(7). 752–758. 9 indexed citations

2.

Rojas, José M., et al.. (2010). BCR-ABL peptide vaccination in healthy subjects: Immunological responses are equivalent to those in chronic myeloid leukaemia patients. Leukemia Research. 35(3). 369–372. 9 indexed citations

3.

Rojas, José M., et al.. (2010). Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Experimental Hematology. 38(12). 1209–1218. 15 indexed citations

4.

Raisi‐Estabragh, Zahra, Katy Knight, Steven Lane, et al.. (2010). A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leukemia Research. 35(1). 49–51. 42 indexed citations

5.

Davies, Andrea, et al.. (2009). Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. Leukemia Research. 34(6). 702–707. 48 indexed citations

6.

Rojas, José M., Katy Knight, L Wang, & Richard E. Clark. (2007). Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 21(11). 2287–2295. 82 indexed citations

7.

Jahnke, Kristoph, Dale F. Kraemer, David Fortin, et al.. (2007). Intra-arterial chemotherapy and osmotic blood-brain barrier disruption for primitive neuroectodermal tumors. Journal of Clinical Oncology. 25(18_suppl). 2046–2046. 1 indexed citations

8.

Wang, Lihui, Katy Knight, Claire Lucas, & Richard E. Clark. (2006). The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.. PubMed. 91(2). 235–9. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact